The strong revenue growth is encouraging but the widening loss and cash burn raise concerns. Monitor for capital raise or restructuring announcements. The next catalyst is the ability to achieve positive cash flow.
Price Chart
Executive Summary
Vivos Therapeutics reported Q1 2026 revenue of $5.14M (+70% YoY, 19.6% above consensus) but EPS of -$0.52 missed estimates by 15.6%. The net loss doubled to $7.75M due to higher operating expenses, including one-time items. The company has negative stockholders' equity and needs additional funding.
Key Financial Metrics
Key Facts
- Revenue $5.14M vs consensus $4.3M (beat by 19.6%)
- EPS -$0.52 vs consensus -$0.45 (miss by 15.6%)
- Gross margin improved to 60% from 50%
- Net loss widened to $7.75M from $3.86M
- Cash $2.1M, stockholders' deficit -$1.1M
Financial Impact
Revenue beat of $0.84M (19.6%) but EPS miss of $0.07 (15.6%)
Risk Factors
- Need for additional funding leading to dilution
- Going concern risk due to negative equity
- High cash burn rate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298869 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1251 (−7.13%) |
Oct 19, 2026 7d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1251 (−11.28%) |
Oct 19, 2026 7d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1251 (−11.02%) |
Oct 15, 2026 12d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1251 (−12.39%) |
Oct 15, 2026 12d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1251 (−12.39%) |
Sep 30, 2026 26d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1251 (+16.04%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1251 (−44.38%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1251 (−54.80%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1251 (+58.47%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1251 (−63.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers